For foreign manufacturers, the US import process is a black box — you ship a container, and it either clears or it does not. Understanding what actually happens at the port between vessel arrival and product release can help you avoid the filing errors, documentation gaps, and compliance failures that cause delays, detentions, and refusals. The import process for FDA-regulated products involves multiple agencies, electronic screening systems, and decision points, and the manufacturer's compliance preparation determines the outcome at every stage.
Pre-arrival: entry filing and Prior Notice
Before a vessel arrives at a US port, the customs broker files entry data through the Automated Commercial Environment (ACE), which transmits it to CBP and FDA. For food, FDA must receive and confirm Prior Notice through PNSI or the CBP filing system no less than 8 hours before arrival by water. Except for international mail, PNSI filings cannot be made more than 15 calendar days before anticipated arrival; ABI/ACS filings (now through the ACE pathway) cannot be made more than 30 calendar days before anticipated arrival. Those are earliest-filing limits, not minimum lead times. Entry data includes the product description, HTS classification, FDA product code, manufacturer food-facility registration number where required, country of origin, value and quantity. ACE routes FDA-regulated entries for FDA review; FDA may screen them before the vessel arrives. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-what-you-need-know-about-prior-notice-imported-food-shipments
Arrival and FDA screening
When the vessel arrives and the container is offloaded, the entry is in 'pending' status with both CBP (for customs clearance) and the FDA (for regulatory clearance). The FDA reviews the entry electronically, checking the manufacturer's registration status, the PREDICT risk score, whether the product or manufacturer is listed on any import alerts, and whether the entry data is consistent and complete. If the entry passes electronic screening — the registration is current, no import alerts apply, the PREDICT score is low, and the data is consistent — the FDA may release the shipment without further examination. This is the best-case scenario, and it is the outcome that well-prepared manufacturers with clean compliance histories typically experience.
Examination, sampling, and holds
If the FDA flags the entry for further review — based on PREDICT score, import alert status, random selection, or specific intelligence — the shipment is placed on hold and may be subjected to document review, label examination, physical examination, or sample collection for laboratory analysis. During a hold, the container remains at the port terminal or is moved to a bonded warehouse. The importer bears all costs — terminal storage, demurrage charges from the shipping line, warehouse fees, and handling charges. These costs accumulate daily and can quickly become significant, especially for perishable products or time-sensitive shipments. Laboratory analysis, if required, can take days to weeks depending on the tests ordered.
FDA decision: release, detention, or refusal
After completing its review or examination, the FDA issues one of three decisions. Release means the product is cleared for import and can proceed to the importer. Detention means the FDA has identified an apparent violation and is holding the product pending further review — the importer receives a Notice of FDA Action describing the suspected violation and has the opportunity to provide evidence that the product is compliant. Refusal means the FDA has determined that the product violates the FD&C Act and is refusing admission — the product must be exported or destroyed within 90 days at the importer's expense. Each detention and refusal is recorded in the FDA's import database and affects the manufacturer's compliance history and future PREDICT scores.
Post-clearance and distribution
Once the FDA releases a shipment, CBP completes the customs clearance process — collecting duties, verifying trade agreement eligibility, and issuing the release. The importer can then take possession of the goods and distribute them into US commerce. However, FDA clearance at the port does not provide immunity from further FDA action — if a product is later found to be adulterated, misbranded, or otherwise non-compliant, the FDA can take enforcement action against the product while it is in US commerce, including seizure, recall, and Warning Letters. Import clearance is not a compliance guarantee; it is a point-in-time admissibility determination.
How FDABridge ensures smooth port clearance
FDABridge ensures that the regulatory prerequisites for smooth import clearance — current facility registration, accurate US Agent designation, and correct product classifications — are in place before your products reach a US port. Products from properly registered facilities with clean compliance histories clear faster and face fewer examinations. Visit fdabridge.com to see our registration services or fdabridge.com/contact to discuss your compliance needs.